FLPIM
AUPH icon

F.L. Putnam Investment Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

F.L. Putnam Investment Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-40,391
Closed -$202K – 729
2024
Q1 		$202K Hold
40,391
– – ﹤0.01% 470
2023
Q4 		$363K Hold
40,391
– – 0.01% 385
2023
Q3 		$314K Buy
+40,391
New +$395K 0.01% 405

Other funds holding AUPH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

F.L. Putnam Investment Management's AUPH Position: Q2 2024 in Review

F.L. Putnam Investment Management sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2024, closing a stake of 40,391 shares — an estimated $202K sold.

F.L. Putnam Investment Management first reported a position in AUPH in Q3 2023 and held it in 3 quarters. The position peaked at $363K in Q4 2023. 171 funds tracked by Wall St. Rank hold AUPH as of Q2 2024.

  • F.L. Putnam Investment Management reported no remaining Aurinia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • F.L. Putnam Investment Management sold 40,391 Aurinia Pharmaceuticals shares in Q2 2024, an estimated $202K.
  • F.L. Putnam Investment Management first reported a position in Aurinia Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • F.L. Putnam Investment Management's Aurinia Pharmaceuticals position peaked at $363K in Q4 2023.
  • 171 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2024.

Based on F.L. Putnam Investment Management's 13F filing for Q2 2024, filed 14 Aug 2024.